Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse

Takashi Taga, Yoshitaka Murakami, Ken Tabuchi, Souichi Adachi, Daisuke Tomizawa, Yasuko Kojima, Koji Kato, Kazutoshi Koike, Katsuyoshi Koh, Ryosuke Kajiwara, Kazuko Hamamoto, Hiromasa Yabe, Keisei Kawa, Yoshiko Atsuta, Kazuko Kudo

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Background: In children with acute myeloid leukemia (AML), hematopoietic stem cell transplantation (HSCT) in first remission is indicated for patients with a relatively high risk of relapse. Second HSCT is a curative option; however, few reports have been published about a second HSCT in children for AML with posttransplantation relapse. Procedure: Using the database provided by the Japanese Society of Hematopoietic Cell Transplantation, we analyzed 46 children with AML who underwent a second allogeneic HSCT after achieving a second remission. Results: The median duration from the first to second HSCT was 20 months, and the source of the second HSCT was related bone marrow (BM) in 22, related peripheral blood in 6, unrelated BM in 14, and unrelated cord blood in 4 patients. Twenty-five children eventually died of the following causes: progressive disease in 14 and transplant-related toxicities in 9. The 5-year overall survival rate was 41.7 ± 7.7%. An interval of less than 24 months between the first and second HSCT was a significant poor prognostic factor. Conclusions: Children with AML who experience a relapse after HSCT in first remission have a good chance of survival with a second HSCT if a second remission is achieved.

    Original languageEnglish
    Pages (from-to)701-705
    Number of pages5
    JournalPediatric Blood and Cancer
    Volume63
    Issue number4
    DOIs
    Publication statusPublished - Apr 1 2016

    Fingerprint

    Hematopoietic Stem Cell Transplantation
    Acute Myeloid Leukemia
    Transplantation
    Recurrence
    Bone Marrow
    Cell Transplantation
    Fetal Blood
    Survival Rate
    Databases
    Transplants
    Survival

    All Science Journal Classification (ASJC) codes

    • Pediatrics, Perinatology, and Child Health
    • Hematology
    • Oncology

    Cite this

    Taga, T., Murakami, Y., Tabuchi, K., Adachi, S., Tomizawa, D., Kojima, Y., ... Kudo, K. (2016). Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse. Pediatric Blood and Cancer, 63(4), 701-705. https://doi.org/10.1002/pbc.25866

    Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse. / Taga, Takashi; Murakami, Yoshitaka; Tabuchi, Ken; Adachi, Souichi; Tomizawa, Daisuke; Kojima, Yasuko; Kato, Koji; Koike, Kazutoshi; Koh, Katsuyoshi; Kajiwara, Ryosuke; Hamamoto, Kazuko; Yabe, Hiromasa; Kawa, Keisei; Atsuta, Yoshiko; Kudo, Kazuko.

    In: Pediatric Blood and Cancer, Vol. 63, No. 4, 01.04.2016, p. 701-705.

    Research output: Contribution to journalArticle

    Taga, T, Murakami, Y, Tabuchi, K, Adachi, S, Tomizawa, D, Kojima, Y, Kato, K, Koike, K, Koh, K, Kajiwara, R, Hamamoto, K, Yabe, H, Kawa, K, Atsuta, Y & Kudo, K 2016, 'Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse', Pediatric Blood and Cancer, vol. 63, no. 4, pp. 701-705. https://doi.org/10.1002/pbc.25866
    Taga, Takashi ; Murakami, Yoshitaka ; Tabuchi, Ken ; Adachi, Souichi ; Tomizawa, Daisuke ; Kojima, Yasuko ; Kato, Koji ; Koike, Kazutoshi ; Koh, Katsuyoshi ; Kajiwara, Ryosuke ; Hamamoto, Kazuko ; Yabe, Hiromasa ; Kawa, Keisei ; Atsuta, Yoshiko ; Kudo, Kazuko. / Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse. In: Pediatric Blood and Cancer. 2016 ; Vol. 63, No. 4. pp. 701-705.
    @article{2f6db7343ed3443287c21fbae04d0e9d,
    title = "Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse",
    abstract = "Background: In children with acute myeloid leukemia (AML), hematopoietic stem cell transplantation (HSCT) in first remission is indicated for patients with a relatively high risk of relapse. Second HSCT is a curative option; however, few reports have been published about a second HSCT in children for AML with posttransplantation relapse. Procedure: Using the database provided by the Japanese Society of Hematopoietic Cell Transplantation, we analyzed 46 children with AML who underwent a second allogeneic HSCT after achieving a second remission. Results: The median duration from the first to second HSCT was 20 months, and the source of the second HSCT was related bone marrow (BM) in 22, related peripheral blood in 6, unrelated BM in 14, and unrelated cord blood in 4 patients. Twenty-five children eventually died of the following causes: progressive disease in 14 and transplant-related toxicities in 9. The 5-year overall survival rate was 41.7 ± 7.7{\%}. An interval of less than 24 months between the first and second HSCT was a significant poor prognostic factor. Conclusions: Children with AML who experience a relapse after HSCT in first remission have a good chance of survival with a second HSCT if a second remission is achieved.",
    author = "Takashi Taga and Yoshitaka Murakami and Ken Tabuchi and Souichi Adachi and Daisuke Tomizawa and Yasuko Kojima and Koji Kato and Kazutoshi Koike and Katsuyoshi Koh and Ryosuke Kajiwara and Kazuko Hamamoto and Hiromasa Yabe and Keisei Kawa and Yoshiko Atsuta and Kazuko Kudo",
    year = "2016",
    month = "4",
    day = "1",
    doi = "10.1002/pbc.25866",
    language = "English",
    volume = "63",
    pages = "701--705",
    journal = "Pediatric Blood and Cancer",
    issn = "1545-5009",
    publisher = "Wiley-Liss Inc.",
    number = "4",

    }

    TY - JOUR

    T1 - Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse

    AU - Taga, Takashi

    AU - Murakami, Yoshitaka

    AU - Tabuchi, Ken

    AU - Adachi, Souichi

    AU - Tomizawa, Daisuke

    AU - Kojima, Yasuko

    AU - Kato, Koji

    AU - Koike, Kazutoshi

    AU - Koh, Katsuyoshi

    AU - Kajiwara, Ryosuke

    AU - Hamamoto, Kazuko

    AU - Yabe, Hiromasa

    AU - Kawa, Keisei

    AU - Atsuta, Yoshiko

    AU - Kudo, Kazuko

    PY - 2016/4/1

    Y1 - 2016/4/1

    N2 - Background: In children with acute myeloid leukemia (AML), hematopoietic stem cell transplantation (HSCT) in first remission is indicated for patients with a relatively high risk of relapse. Second HSCT is a curative option; however, few reports have been published about a second HSCT in children for AML with posttransplantation relapse. Procedure: Using the database provided by the Japanese Society of Hematopoietic Cell Transplantation, we analyzed 46 children with AML who underwent a second allogeneic HSCT after achieving a second remission. Results: The median duration from the first to second HSCT was 20 months, and the source of the second HSCT was related bone marrow (BM) in 22, related peripheral blood in 6, unrelated BM in 14, and unrelated cord blood in 4 patients. Twenty-five children eventually died of the following causes: progressive disease in 14 and transplant-related toxicities in 9. The 5-year overall survival rate was 41.7 ± 7.7%. An interval of less than 24 months between the first and second HSCT was a significant poor prognostic factor. Conclusions: Children with AML who experience a relapse after HSCT in first remission have a good chance of survival with a second HSCT if a second remission is achieved.

    AB - Background: In children with acute myeloid leukemia (AML), hematopoietic stem cell transplantation (HSCT) in first remission is indicated for patients with a relatively high risk of relapse. Second HSCT is a curative option; however, few reports have been published about a second HSCT in children for AML with posttransplantation relapse. Procedure: Using the database provided by the Japanese Society of Hematopoietic Cell Transplantation, we analyzed 46 children with AML who underwent a second allogeneic HSCT after achieving a second remission. Results: The median duration from the first to second HSCT was 20 months, and the source of the second HSCT was related bone marrow (BM) in 22, related peripheral blood in 6, unrelated BM in 14, and unrelated cord blood in 4 patients. Twenty-five children eventually died of the following causes: progressive disease in 14 and transplant-related toxicities in 9. The 5-year overall survival rate was 41.7 ± 7.7%. An interval of less than 24 months between the first and second HSCT was a significant poor prognostic factor. Conclusions: Children with AML who experience a relapse after HSCT in first remission have a good chance of survival with a second HSCT if a second remission is achieved.

    UR - http://www.scopus.com/inward/record.url?scp=84959542750&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84959542750&partnerID=8YFLogxK

    U2 - 10.1002/pbc.25866

    DO - 10.1002/pbc.25866

    M3 - Article

    C2 - 26670954

    AN - SCOPUS:84959542750

    VL - 63

    SP - 701

    EP - 705

    JO - Pediatric Blood and Cancer

    JF - Pediatric Blood and Cancer

    SN - 1545-5009

    IS - 4

    ER -